Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus

Postgraduate Medicine

Volumn 129, Issue 8, 2017, Pages 811-821

  Yandrapalli, Srikanth ^a   Jolly, George ^a   Horblitt, Adam ^a   Sanaani, Abdallah ^a   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

cardiovascular effects; Diabetes mellitus; empagliflozin; glucagon like peptide 1 agonists; liraglutide; sodium glucose co transporter 2 inhibitors; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INCRETIN; LIRAGLUTIDE; LIXISENATIDE; MEGLITINIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; BENZAMIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOSIDASE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; BODY WEIGHT DISORDER; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SAFETY; FLATULENCE; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETIC ANGIOPATHY; RISK FACTOR;

BENZAMIDES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSIDE HYDROLASE INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 85026394482     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.1080/00325481.2017.1358064     Document Type: Review

References (112)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta [cited 2017 Jan27]. Available from: https://www.cdc.gov/diabetes/data/statistics/2014StatisticsReport.html
2. International Diabetes Federation. [cited 2017 Jan27]. Available from: http://www.idf.org/about-diabetes/facts-figures
3. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
4. Di Angelantonio E, Kaptoge S, Wormser D, et al. The emerging risk factors collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60.
5. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431.
6. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720–1732.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
8. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
9. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
10. Obunai K, Jani S, Dangas GD., Cardiovascular morbidity and mortality of the metabolic syndrome. Med Clin North Am. 2007;91:1169–1184.
11. Towfighi A, Ovbiagele B., Metabolic syndrome and stroke. Curr Diab Rep. 2008;8(1):37–41.
12. Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156.
13. Defronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1991;73(6):1294–1301.
14. Viollet B, Guigas B, Garcia NS, et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253–270.
15. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426–435.
16. Lee H, Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl Environ Microbiol. 2014 Oct;80(19):5935–5943.
17. Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017 May 22 [Epub ahead of print]. DOI:10.1038/nm.4345.
18. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5:6.
19. De Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. Bmj. 2010;340(may19 4):c2181–c2181.
20. Gan SC, Barr J, Arieff AI, et al. Biguanide-associated lactic acidosis. Case report and review of the literature. Arch Intern Med. 1992;152(11):2333–2336.
21. Azimova K, Juan ZS, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014;14(4):616–632.
22. Seifarth. Eff ectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(121):27–31. DOI:10.1055/s-0032-1327734.
23. Messaoudi SE, Rongen GA, de Boer RA, et al. The cardioprotective effects of metformin. Curr Opin Lipidol. 2011;22:445–453.
24. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type. 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865.
25. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
26. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Int Med. 2008;168:2070–2080.
27. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004 May-Jun;20(3):239–245.
28. Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111(5):583–590.
29. Shah DD, Fonarow GC, Horwich TB. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Cardiac Failure. 2010;16:200–206.
30. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circ Hear Fail. 2013;6(3):395–402.
31. Romero SP, Andrey JL, Garcia-Egido A, et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol. 2013;166(2):404–412.
32. Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother. 2012;1:1–8.
33. Food and Drug Administration. Product label approval: metformin. 2006 [cited 2017 May20]. Available from: http://packageinserts.bms.com/pi/piglucophage.pdf
34. Seino S, Takahashi H, Takahashi T, et al. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes, Obes Metab. 2012;14:9–13.
35. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423–426.
36. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157(8):836–848.
37. Schopman JE, Simon ACR, Hoefnagel SJM, et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014;30(1):11–22.
38. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pr. 1991;14(Suppl 2):S21–36.
39. Chen YH, Du L, Geng XY, et al. Effects of sulfonylureas on lipids in Type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Evid Based Med. 2015;8:134–148.
40. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999 Mar;20(6):439–446.
41. Hausenloy DJ, Wynne AM, Mocanu MM, et al. Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. J Cardiovasc Pharmacol Ther. 2013 May;18(3):263–269.
42. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972;21:976–979.
43. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32(15):1900–1908.
44. Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes, Obes Metab. 2012;14(9):803–809.
45. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(10):938–953.
46. Varvaki Rados D, Catani Pinto L, Reck Remonti L, et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;13(4):e1001992.
47. Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care. 2017 May;40(5):706–714.
48. Riddle MC. Modern sulfonylureas: dangerous or wrongly accused? Diabetes Care May. 2017;40(5):629–631.
49. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118.
50. Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 2000;49(5):827–831.
51. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572–2581.
52. Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J. 2007;153(3):445.e1-e6.
53. Wajcberg E, Sriwijitkamol A, Musi N, et al. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab. 2007;92(4):1256–1262.
54. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573.
55. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–1554.
56. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2008 Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. [cited 2017 Jan27]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf
57. European Medicine Agency, Committee for Medicinal Products for Human Use, 2010 Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. [cited 2017 Jan27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf
58. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–1195.
59. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191–1201.
60. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289.
61. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188.
62. Winkelmayer WC, Setoguchi S, Levin R, et al. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008;168(21):2368–2375.
63. Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Bmj. 2009;339(aug182):b2942–b2942.
64. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
65. Nakamura T, Yamamoto E, Kataoka K, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke. 2007 Nov;38(11):3016–3022.
66. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care. 1997;20(3):248–253.
67. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care. 2000;23(8):1162–1167.
68. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care. 1999;22(6):960–964.
69. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med. 1997;103(6):483–490.
70. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494.
71. Van De Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005;28(1):154–163.
72. Hariya N, Mochizuki K, Inoue S, et al. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients. Drugs R D. 2014;14(3):177–184.
73. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47(3):345–351.
74. Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract. 2003;60(3):161–169.
75. NAVIGATOR Study Group, Holman RR, Haffner SM, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–1476.
76. Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60:470–512.
77. Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metabolism. 2015;6:19–28.
78. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
79. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
80. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
81. Lorber D. GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther. 2013;31:238–249.
82. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1770.
83. Lonborg J, Kelbæk H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5:288–295.
84. Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55:926–935.
85. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27:130–139.
86. Sun F, Wu S, Wang J, et al. Effect of glucagonlike peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37:225–241.
87. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.
88. Kim HJ, Kim DJ. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes. J Diabetes Investig. 2016 Dec 8 [Epub ahead of print]. DOI:10.1111/jdi.12607.
89. Koska J, Sands M, Burciu C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:154–163.
90. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227:349–354.
91. Monami M, Lamanna C, Desideri CM, et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14–25.
92. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
93. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.
94. White WB. Cardiovascular outcomes with alogliptin in patients with type 2 diabetes mellitus and recent acute coronary syndromes. In: Presented at European Association for the Study of Diabetes; 2013 Sep 23–27; Barcelona, Spain. Diabetologia. 2013 Sep;56 Suppl 1:1–566.
95. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
96. Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
97. Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374:1145–1154.
98. Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, et al. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials. Int J Cardiol. 2016 May 15;211:88–95.
99. Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure. [cited 2017 May20]. Available from: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
100. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–110.
101. Triggle CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014;5(6):245–268.
102. Kumar R, Kerins DM, Walther T. Cardiovascular safety of anti-diabetic drugs. Eur Heart J Cardiovasc Pharmacother. 2016;2(1):32–43.
103. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium- glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262–275.
104. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330–333.
105. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
106. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
107. Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2016. DOI:10.1681/ASN.2016030278.
108. Wanner SE, Inzucchi JM, Lachin D, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
109. CANVAS (clinicaltrials.gov identifier: NCT01032629).
110. DECLARE-TIMI58 (clinicaltrials.gov identifier: NCT01730534).
111. Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (clinicaltrials.gov identifier: NCT01986881).
112. Kosiborod M, Cavender M, Norhammar A, et al. Lower rates of hospitalization for heart failure and all-cause death in new users of sglt-2 inhibitors versus other glucose lowering drugs–real world data from six countries and more than 300,000 patients: the cvd-real study. In: Presented at American College of Cardiology Scientific Sessions; 2017 Mar [cited 2017 May20]; Washington (DC). Available from: https://www.acc.org/latest-in-cardiology/articles/2017/03/13/17/58/sun-2pm-cvd-real-study-lower-rates-of-hospitalization-for-hf-in-new-users-of-sglt-2-inhibitors-vs-other-glucose-lowering-drugs-acc-2017#sthash.ZrcVp77F.dpuf